To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Recruitment & Eligibility

Inclusion Criteria

Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
Evaluable tumour deposits by one or more techniques (X-ray, CT, MRI, ultrasound)
Age 18 years or older
Life expectancy of at least three months
Patients had to give written informed consent (which must be consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) and local legislation)
Eastern Cooperative Oncology Group (ECOG) performance score < 2
Full recovery from all therapy-related toxicities from previous chemo-, hormone-,immuno-, or radiotherapy

Exclusion Criteria

History of relevant surgical procedures during the last four weeks prior to treatment with the trial drug, or active ulcers, or injuries with incomplete wound healing
Pregnancy or breastfeeding
Active infectious disease
Brain metastases requiring therapy
Absolute neutrophil count less than 1500 / mm3
Platelet count less than 100 000 / mm3
Bilirubin greater than 1.5 mg / dl (> 26 μmol / L, International System of Units (SI unit) equivalent)
Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
Serum creatinine greater than 1.5 mg / dl (> 132 μmol / L, SI unit equivalent)
Uncontrolled, severe hypertension
Gastrointestinal disorders anticipated to interfere with the resorption of the study drug
Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
Patients unable to comply with the protocol
Active alcohol or drug abuse

Study & Design

Arm && Interventions

Group	Intervention	Description
BIBF 1120	BIBF 1120	-

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose of BIBF 1120	up to 30 days

Secondary Outcome Measures

Name	Time	Method
Change in Eastern Cooperative Oncology Group (ECOG) score	up to 4 months
Mean plasma level of vascular endothelial growth factor (VEGF)	10 hours after drug intake
Mean plasma level of basic fibroblast growth factor (bFGF)	10 hours after drug intake
Time to tumour progression	up to 4 months
Overall best investigator assessment of tumour response	up to 4 months
Overall best calculated assessment of tumour response	up to 4 months
Number of patients with response in transfer of contrast medium into tissue (Ktrans)	up to 4 months
Number of patients with response in initial area under the curve for first 60 seconds after onset of gadolinium uptake (iAUC60)	60 seconds

Recruitment & Eligibility